We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Kallikrein

Kallikrein inhibitors block plasma and tissue kallikreins, serine proteases that release kinin peptides. Plasma kallikrein circulates as an inactive precursor and is activated together with coagulation factor XII during contact activation. The active enzyme cleaves high-molecular-weight kininogen to release bradykinin, a peptide that raises vascular permeability. Tissue kallikrein and the kallikrein-related peptidases (KLK1 to KLK15) form a separate family of secreted proteases studied in skin biology and cancer. Sebetralstat and berotralstat inhibit plasma kallikrein, while Kallikrein 5-IN-2 acts on KLK5 and FE-999024 on tissue kallikrein. D-Pro-Phe-Arg-Chloromethylketone blocks both factor XII and kallikrein, the two proteases that start contact activation. The chromogenic substrate D-Val-Leu-Arg-pNA acetate is used to measure kallikrein activity in enzyme assays.

1 Item

  • D-Val-Leu-Arg-pNA acetate
    Cat. No.
    A64965
    CAS No.
    162303-66-4

    D-Val-Leu-Arg-pNA acetate

    D-Val-Leu-Arg-pNA acetate serves as a substrate for the serine protease kallikrein. It enables the assessment of kallikrein activity through the release of p-nitroaniline upon peptide cleavage. This compound is valuable for research applications focused on the role of kallikrein in various physiological and pathological processes, providing insights into its functions in inflammation and fluid regulation.

    In stock View Details
    1 mg
    $85.00
    5 mg
    $215.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...